10 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 8 with minor changes only.
Primary endpoint(s) modified
Also in this update: Sponsor changed: BeiGene to BeOne Medicines; Results posted: Sep 22, 2026
BeOne MedicinesPhase 1/2 NCT05471843 Registry history of NCT05471843 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Sep 24, 2026 to Sep 25, 2026
BeOne MedicinesPhase 1 NCT07820891 Registry history of NCT07820891 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 30, 2026 to Oct 31, 2026
BeOne MedicinesPhase 1 NCT07590102 Registry history of NCT07590102 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Nov 2026 to Mar 2027
Also in this update: Study completion pushed from Nov 2029 to Mar 2030
BeOne MedicinesPhase 1/2 NCT05006716 Registry history of NCT05006716 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 189 → 206 locations
And 1 more change in the last 30 days
BeOne MedicinesPhase 3 NCT07492641 Registry history of NCT07492641 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 1 → 6 locations
BeOne MedicinesNot specified NCT07652736 Registry history of NCT07652736 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 155 → 150 locations
BeOne MedicinesPhase 3 NCT06742996 Registry history of NCT06742996 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 214 → 217 locations
BeOne MedicinesPhase 3 NCT06973187 Registry history of NCT06973187 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 17 → 20 locations
BeOne MedicinesPhase 1/2 NCT06697184 Registry history of NCT06697184 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Mar 2027 to Apr 27, 2026
BeOne MedicinesPhase 3 NCT04002297 Registry history of NCT04002297 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-19 | NCT07881211 A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody… | Phase 1 | Not Yet Recruiting |
| 2026-10-02 | NCT07855991 A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in… | Phase 1 | Not Yet Recruiting |
| 2026-10-02 | NCT07856004 A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg… | Phase 1 | Not Yet Recruiting |
| 2026-09-23 | NCT07836530 Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular… | Phase 3 | Not Yet Recruiting |
| Phase 1 | 25 | |
| Phase 1/2 | 8 | |
| Phase 2 | 4 | |
| Phase 2/3 | 1 | |
| Phase 3 | 14 |
Leukemia (11) · Chronic Lymphocytic Leukemia (CLL) (9) · Non-Hodgkin Lymphoma (8) · Mantle Cell Lymphoma (5) · Breast Cancer (4) · Gastric Cancer (3) · Acute Myeloid Leukemia (AML) (2) · DLBCL (2) · Esophageal Cancer (2) · Follicular Lymphoma (2)